New prescription allergy treatment Xyzal now available for fall allergy season in the U.S.
PARIS UCB and Sanofi-Aventis’ new once-daily medication used to treat indoor and outdoor allergies, is now available by prescription in the United States, the companies said Tuesday.
Xyzal is an oral antihistamine that has been shown to provide powerful allergy symptom relief, and is approved for use in adults and children 6 years and older.
“Allergy patients need a prescription treatment option that works quickly to relieve their suffering,” said Michael Blaiss, clinical professor of pediatrics and medicine at the University of Tennessee Health Science Center in Memphis, Tennessee. “It is important for people living with allergies to work with their physician to develop an appropriate allergy treatment plan that will effectively reduce their symptoms.”
The Food and Drug Administration approved Xyzal in May. Last year, UCB and Sanofi-Aventis entered into an agreement to launch and co market Xyzal in the United States.
Xyzal is currently marketed in more than 80 countries worldwide, including the European Union. The FDA approval is based primarily upon the results of eight randomized, placebo-controlled clinical trials involving over 2,000 patients.
Mylan announces new appointments
PITTSBURGH Upon the news of the acquisition involving Merck’s KGaA generic business by Mylan, Mylan released a group of statements regarding new appointments to positions within the company worldwide.
The appointments include: Harry Korman as President, North America; Rajiv Malik as Executive Vice President in charge or Global Technical Operations; Carolyn Myers, Ph.D. President-elect of Dey; Christy Taylor as Chief Operating Officer of Dey; Didier Barret as President of Europe, Middle East, and Africa; Heather Bresch as Chief Operating Officer; and John Montgomery as President, Asia Pacific.
Mylan acquired Merck’s generics for $6.8 billion in cash.
FDA approves Afluria flu vaccine
AUSTRALIA The Food and Drug Administration has approved CSL’s flu vaccine Afluria, according to The Australian.
The company expects to ship two million doses as part of its first shipment to the U.S. between mid-December and early February. The company expects to increase its export to 20 million doses over the next four years.
“We’ve entered the US market quite late, but over the next few years we hope to increase our export of flu vaccine to the US to 20 million doses,” CSL’s Dr Rachel David said.